SCHEMBL7074897

SCHEMBL7074897

c1ccc(CC2CC3CCC2CN3Cc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 3/20 0.55
GRIN1 Q05586 2/20 0.55
GAA P10253 1/20 0.44
DRD4 P21917 5/20 0.44
DRD3 P35462 3/20 0.44
CYP2D6 P10635 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
IDO1 P14902 1/20 0.43
HTT P42858 1/20 0.43
TPH1 P17752 1/20 0.41
TPH2 Q8IWU9 1/20 0.41
PDE10A Q9Y233 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073119 0.92 DRD4 (0.46) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL6943195 0.85 GRIN1 (0.39) GRIN2BGRIN1DRD4DRD3CYP2D6
SCHEMBL6944211 0.77 DRD4 (0.36) DRD4DRD3
SCHEMBL7075661 0.77 GRIN2B (0.53) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7072578 0.76 GRIN2B (0.67) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7079132 0.74 GRIN2B (0.50) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7079128 0.74 GRIN2B (0.50) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7676062 0.74 GRIN2B (0.50) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7071755 0.73 GRIN2B (0.62) GRIN2BGRIN1GAADRD4DRD3
SCHEMBL7068562 0.73 GRIN2B (0.62) GRIN2BGRIN1GAADRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248617-A4 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-05 EP claimed
US-6489477-B1 NMDA NR2B ANTAGONISTS. ACCORDINGLY, ANOTHER ASPECT OF THE INVENTION IS THE TREATMENT OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE--MALADIES THAT ARE AMENABLE TO AMELIORATION THROUGH MERCK & CO., INC. 2002-12-03 US claimed
EP-1248617-A1 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-16 EP claimed
WO-2001032177-A1 2-AZA-BICYCLO[2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO claimed
EP-1248617-A4 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-05 EP disclosed
US-6489477-B1 NMDA NR2B ANTAGONISTS. ACCORDINGLY, ANOTHER ASPECT OF THE INVENTION IS THE TREATMENT OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE--MALADIES THAT ARE AMENABLE TO AMELIORATION THROUGH MERCK & CO., INC. 2002-12-03 US disclosed
EP-1248617-A1 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-16 EP disclosed
WO-2001032177-A1 2-AZA-BICYCLO[2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed